Total Valuation
Avalyn Pharma Inc has a market cap or net worth of $1.32B. The enterprise value is $0.00.
Market Cap$1.32B
Enterprise Value$0.00
Share Statistics
Avalyn Pharma Inc has 44,333,096 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,333,096
Owned by Insiders29.18%
Owned by Institutions―
Financial Efficiency
Avalyn Pharma Inc’s return on equity (ROE) is 0.36 and return on invested capital (ROIC) is -67.51%.
Return on Equity (ROE)0.36
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-67.51%
Return on Capital Employed (ROCE)-0.68
Revenue Per Employee0.00
Profits Per Employee-1.70M
Employee Count50
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Avalyn Pharma Inc is ―. Avalyn Pharma Inc’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio-5.17
Price to Fair Value-5.17
Price to FCF-15.07
Price to Operating Cash Flow-15.26
PEG Ratio0.00
Income Statement
In the last 12 months, Avalyn Pharma Inc had revenue of 0.00 and earned -85.20M in profits. Earnings per share was -2.04.
Revenue0.00
Gross Profit0.00
Operating Income-91.29M
Pretax Income-85.20M
Net Income-85.20M
EBITDA-91.25M
Earnings Per Share (EPS)-2.04
Cash Flow
In the last 12 months, operating cash flow was -29.89M and capital expenditures -318.00K, giving a free cash flow of -30.21M billion.
Operating Cash Flow-29.89M
Free Cash Flow-30.21M
Free Cash Flow per Share-0.68
Dividends & Yields
Avalyn Pharma Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change0.81%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)931.19K
Important Dates
Avalyn Pharma Inc upcoming earnings date is Jun 3, 2026, Before Open (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateJun 3, 2026
Ex-Dividend Date―
Financial Position
Avalyn Pharma Inc as a current ratio of 10.19, with Debt / Equity ratio of -0.70%
Current Ratio10.19
Quick Ratio10.19
Debt to Market Cap0.00
Net Debt to EBITDA0.56
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Avalyn Pharma Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Avalyn Pharma Inc EV to EBITDA ratio is -12.96, with an EV/FCF ratio of -14.45.
EV to Sales0.00
EV to EBITDA-12.96
EV to Free Cash Flow-14.45
EV to Operating Cash Flow-14.51
Balance Sheet
Avalyn Pharma Inc has $123.13M in cash and marketable securities with $16.41M in debt, giving a net cash position of $106.72M billion.
Cash & Marketable Securities$123.13M
Total Debt$16.41M
Net Cash$106.72M
Net Cash Per Share$2.41
Tangible Book Value Per Share-$5.71
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Avalyn Pharma Inc is $52.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$52.00
Price Target Upside― Downside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―